- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.10. | Merck kidney cancer drug succeeds in two large trials | ||
| 28.10. | Incyte trims pipeline; Zenas surges on MS drug results | ||
| 28.10. | Zag Bio emerges with plans to treat immune disease by targeting the thymus | ||
| 27.10. | BioMarin, following sluggish sales, to offload hemophilia gene therapy | ||
| 27.10. | Intellia pauses two CRISPR drug studies after safety scare | ||
| 27.10. | Bayer receives FDA approval for non-hormonal menopause therapy | ||
| 27.10. | BridgeBio to seek approval of limb-girdle drug following new study data | ||
| 27.10. | Hemab collects another $157M to go after 'underserved' blood diseases | ||
| 27.10. | Community pharmacies and BioPharma: Advancing whole-patient care together | ||
| 27.10. | Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease | ||
| 24.10. | Biogen licenses a possible immune drug from OrbiMed-backed biotech | ||
| 24.10. | Adverum, hammered by gene therapy downturn, sells to Lilly in unusual deal | ||
| 24.10. | Sanofi says 'soft' start to fall immunizations slowed vaccine sales | ||
| 24.10. | Chugai buys a kidney biotech; ICER targets rising launch prices | ||
| 24.10. | FDA clears return of GSK's once-withdrawn multiple myeloma drug | ||
| 23.10. | Ventyx shares soar after study suggests cardiovascular benefits for experimental drug | ||
| 22.10. | Sanofi drug acquired in buyout succeeds in rare disease trial | ||
| 22.10. | Alkermes expands sleep portfolio with acquisition worth up to $2.1B | ||
| 22.10. | Alector dementia drug, partnered with GSK, fails in key study | ||
| 22.10. | Takeda stakes more than $11B on cancer drugs from China | ||
| 22.10. | Electra nabs $183M for its rare disease drug ambitions | ||
| 22.10. | Flagship bets again on AI with Expedition | ||
| 21.10. | Novo's main shareholder pushes out more than half of company's board | ||
| 21.10. | Iambic partners with Jazz Pharmaceuticals; Merck breaks ground on $3B plant | ||
| 21.10. | Galapagos to wind down cell therapy business after failed attempt at sale |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .